Research

Hormonal

Tirzepatide treatment (5-15 mg weekly for 72 weeks) significantly improves both insulin sensitivity and beta-cell function in adults with obesity or overweight (BMI ≥27 kg/m2) with prediabetes or normoglycemia, independent of type 2 diabetes.

If you have obesity or are overweight and have prediabetes or normal blood sugar, tirzepatide (a once-weekly injection) can significantly improve how your body handles insulin and how well your pancreas functions. This happens partly because you lose weight, but also directly from the medication itself, potentially lowering your risk of developing type 2 diabetes.

GoodSupportsHIGH confidence
Tirzepatide treatment was associated with improved insulin sensitivity (strongly related to decreased body weight and partially related to tirzepatide treatment) and β-cell function (strongly associated with tirzepatide treatment) in this population, irrespective of glycemic status.
Andrea Mari et al. · Diabetes Care · 2025

Why this rating

Post hoc analysis of a large, randomized, double-blind, placebo-controlled trial (SURMOUNT-1).

Source

Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial

Andrea Mari et al. · Diabetes Care · 2025

DOI 10.2337/dc25-0763

rct · n=2539Cited 7×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →